Nife-Par (Nifedipine)

Nifedipine, the active ingredient in Nife-Par, is a calcium channel blocker (dihydropyridine) presented as an oral tablet for oral use. It treats hypertension, chronic stable angina, and Raynaud's phenomenon in adult patients.

GNH USA supplies Nife-Par as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nifedipine acts on the vascular smooth‑muscle calcium channels to lower blood pressure and relieve myocardial oxygen demand, making it useful in several cardiovascular conditions.

- Hypertension: reduces peripheral vascular resistance to achieve blood‑pressure control. - Chronic stable angina: improves coronary blood flow and decreases frequency of anginal episodes. - Raynaud's phenomenon: alleviates vasospasm in peripheral arteries, reducing attacks.

Nifedipine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of ankles or feet. - Dizziness or light‑headedness, especially on standing. - Reflex tachycardia: increased heart rate. - Nausea or abdominal discomfort.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure. - Myocardial infarction: rare but possible in high‑risk patients. - Atrioventricular block: conduction abnormalities. - Hepatic dysfunction: elevated liver enzymes. - Severe allergic reactions: rash, itching, swelling. - Life‑threatening arrhythmias.

Before prescribing Nife-Par, clinicians should evaluate patient history and monitor for specific concerns.

- Cardiovascular assessment: ensure patient is not in acute heart failure. - Concomitant vasodilators: avoid additive hypotensive effects. - Liver function: adjust if hepatic impairment is present. - Elderly patients: start with lower doses and monitor closely. - Grapefruit juice: advise avoidance as it may increase drug levels. - Store at ambient temperature: keep below 25 °C, retain in original container, protect from moisture and direct sunlight.

Nifedipine can interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may cause toxic plasma concentrations. - Simultaneous use with other potent vasodilators: risk of severe hypotension. - Phenytoin or carbamazepine: may reduce nifedipine effectiveness.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask tachycardia, requiring heart‑rate monitoring. - Digoxin: increased serum levels possible; monitor renal function. - Diuretics: may enhance hypotensive effect; adjust fluid status as needed.